• Explore /
  • Poster
  • / Fruquintinib combined with sintilimab as a second-line therapy for advanced gastric and gastroesophageal junction adenocarcinoma (GC/GEJC): A phase II, single‑arm, prospective study.

Fruquintinib combined with sintilimab as a second-line therapy for advanced gastric and gastroesophageal junction adenocarcinoma (GC/GEJC): A phase II, single‑arm, prospective study.

Abstract Poster

Authors

null

Min Jin

Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China

Min Jin , Shengli Yang , Junli Liu , Jieying Zhang , Lei Zhao , Dandan Yu , Zhenyu Lin , Pindong Li , Jing Wang , Jun Xue , Hong Ma , Jianli Hu , Tao Zhang , Hongli Liu

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2024 ASCO Gastrointestinal Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session A: Cancers of the Esophagus and Stomach and Other Gastrointestinal Cancers

Track

Esophageal and Gastric Cancer,Other GI Cancer

Sub Track

Therapeutics

Clinical Trial Registration Number

NCT05625737

Citation

J Clin Oncol 42, 2024 (suppl 3; abstr 332)

DOI

10.1200/JCO.2024.42.3_suppl.332

Abstract #

332

Poster Bd #

F12

Abstract Disclosures

Similar Posters

First Author: Xiangrui Meng

First Author: Li Jingjing

First Author: Shuiling Jin

First Author: Timothy Jay Price